RCEL

NEUTRALEarnings

Avita Medical, Inc.

2026-10-23

Price

$15.51

+1.44%

This is the 2026-10-23 snapshot — the signals and analysis for RCEL as of this single trading day.

View full RCEL research hub →

Score1.1Noise

Signals4/8 DNA0/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.5xvs 20d avg

Analysis

Avita Medical (RCEL) is exhibiting High-Conviction Price Discovery as it perfectly consolidates a massive 249.3% one-month surge. The underlying catalyst is a profound fundamental turnaround, driven by raised full-year guidance and an accelerated path to Q4 cash-flow breakeven. Despite a CAUTION macro regime marked by rising oil prices and a VIX of 19.0, RCEL is shrugging off systemic headwinds, evidenced by its +251.1% relative strength versus the SPY. This signals heavy institutional absorption and a firm refusal by buyers to relinquish shares ahead of the upcoming Q3 earnings print.

Fired Signals

ALPHA MALEGOLDEN CROSSMARKET LEADERPERFECT STACKEXTENSION

Key Takeaways

Actionable Thesis: RCEL's PERFECT_STACK and MARKET_LEADER signals, combined with its ability to hold near recent highs during macro turbulence, suggest strong continuation potential.
Key Risk: With realized volatility at an extreme 247.1% annualized, the stock is highly sensitive to any execution missteps or broader market liquidity shocks.
What to Watch: Price action heading into the November 5th earnings call, specifically looking for volume expansion to confirm the next leg higher, while monitoring the $4.40 structural support.

← Back to 2026-10-23 View Full RCEL History →Yahoo Finance &nearr;